18 completed, 3 unknown, 3 withdrawn, 2 terminated. 12 Phase 2, 6 Phase 3, 5 Phase 4, 3 Phase 1, 1 Not applicable.
Follow Pegylated Interferon: new trials by email Literature Review of Pegylated Interferon trials Research Report on Pegylated Interferon
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Study of Hepalatide in Subjects With Chronic Hepatitis B Hepalatide 2.1mg, Hepalatide 4.2mg, Hepalatide 6.3mg - Hepatitis B, Chronic | Phase 2 | Completed | Shanghai HEP Pharmaceutical Co., Ltd. | 96 | 2021-06-18 | 2025-01-27 |
| A Real-World Study of Pegylated Interferon In Nucleoside-treated Patients With Chronic Hepatitis B Pegylated interferon, Entecavir, Tenofovir disoproxil fumarate - Chronic Hepatitis B | Phase 4 | Unknown | Tongji Hospital | 2000 | 2018-01-25 | 2018-04-25 |
| Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066) Grazoprevir/Elbasvir, Boceprevir, PegIntron - Hepatitis C | Phase 3 | Withdrawn | Merck Sharp & Dohme LLC | 2014-11-01 | 2015-10-14 | |
| Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients BI 201335, ribavirin, BI 207127 - Hepatitis C, Chronic | Phase 3 | Withdrawn | Boehringer Ingelheim | 2013-05-01 | 2014-01-23 | |
| Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B REP 2139-Ca, pegylated interferon, entecavir - Hepatitis B, Chronic | Phase 2 | Completed | Replicor Inc. | 5 | 2012-10-01 | 2019-05-08 |
| Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients midazolam, BI 201335, tenofovir - Hepatitis C, Chronic | Phase 1 | Completed | Boehringer Ingelheim | 72 | 2012-04-01 | 2016-06-10 |
| Long Term Vitamin D Therapy in HCV Treated Patients Vitamin D - Chronic Hepatitis C | Phase 3 | Terminated | Dr. Nadia AbdelAaty AbdelKader | 100 | 2012-04-01 | 2013-11-28 |
| Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus Daclatasvir, Ribavirin, PEG-Interferon alfa 2a - Hepatitis C, Genotype 1 | Phase 3 | Completed | Bristol-Myers Squibb | 549 | 2011-12-01 | 2016-01-29 |
| Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders CTS-1027, pegylated interferon, Ribavirin - Hepatitis C | Phase 2 | Terminated | Conatus Pharmaceuticals Inc. | 114 | 2011-01-01 | 2012-06-11 |
| Y- Shaped Pegylated Interferon (YPEG-IFNα-2a) Plus Ribavirin in Egyptian Patients With Untreated Chronic Hepatitis C pegylated interferon alpha 2a YPEG-IFN α-2a 180mcg - Self Efficacy, Hepatitis C | Phase 2 / Phase 3 | Unknown | BioGeneric Pharma | 300 | 2010-11-01 | 2011-04-04 |
| Study of CTS-1027 in Combination With Pegylated Interferon and Ribavirin in Hepatitis C Virus (HCV) Null-Responders CTS-1027, Pegylated interferon, Ribavirin - Hepatitis C | Phase 2 | Completed | Conatus Pharmaceuticals Inc. | 67 | 2010-01-01 | 2012-04-16 |
| A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028) Vaniprevir 600 mg b.i.d., Vaniprevir 300 mg b.i.d., Pegylated interferon - Hepatitis C, Chronic | Phase 2 | Completed | Merck Sharp & Dohme LLC | 45 | 2009-10-23 | 2021-02-08 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection ABT-333, Placebo for ABT-333, Pegylated interferon - Chronic Hepatitis C Virus Infection | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 30 | 2009-03-01 | 2018-07-02 |
| Effect of Insulin Resistance on the Safety and Efficacy of Pegylated Interferon and Ribavirin Treatment in HCV (Study P05562) Pegylated Interferon, Ribavirin - Hepatitis C, Chronic, Hepatitis C Virus | Completed | Merck Sharp & Dohme LLC | 250 | 2008-05-01 | 2015-07-01 | |
| The Effect of Adding Metformin to the Treatment of Hepatitis C Metformin, pegylated interferon, Ribavirin - Hepatitis C | Phase 4 | Completed | Tehran University of Medical Sciences | 140 | 2007-12-01 | 2015-04-06 |
| Role of Heme Oxygenase in the Pathogenesis of Hepatocellular Injury in Chronic Hepatitis C Virus (HCV) Infection pegylated interferon, Ribavarin - Chronic HCV Infection, Nonalcoholic Steatohepatitis | Not applicable | Unknown | Charles University, Czech Republic | 150 | 2007-01-01 | 2009-02-12 |
| HEPMET-1: Evaluate the Feasibility, Mental Sideeffects and the Efficacy of Hepatitis C Treatment in a MMT Group. Ribavirin, Pegylated Interferon - Opiate Dependence, Hepatitis | Phase 3 | Completed | Sorlandet Hospital HF | 10 | 2006-03-01 | 2008-03-28 |
| Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment Tipranavir, Ritonavir, Pegylated interferon - Hepatic Insufficiency | Phase 1 | Completed | Boehringer Ingelheim | 36 | 2006-01-01 | 2025-01-22 |
| Orthotopic Liver Transplant (OLT) Recipients With Hepatitis C Virus (HCV) Under Preemptive Treatment Pegylated Interferon, Ribavirin, Liver Biopsy - Hepatitis C | Phase 4 | Withdrawn | The University of Texas Health Science Center, Houston | 2005-01-01 | 2013-11-19 | |
| Valopicitabine Alone and Together With Pegylated Interferon in Patients With Chronic Hepatitis C Who Have Failed to Respond to Standard Therapy valopicitabine, pegylated interferon, ribavirin - Chronic Hepatitis C | Phase 2 | Completed | Merck Sharp & Dohme LLC | 2005-01-01 | 2010-06-10 |
Showing 20 of 27. Sign in to see all of them.
Hepatitis C (15) · Hepatitis C, Chronic (8) · Hepatitis B, Chronic (4) · Hepatitis (3) · Digestive System Diseases (1) · Enterovirus Infections (1) · Flaviviridae Infections (1) · HIV Infections (1) · Hepatic Insufficiency (1) · Hepatitis, Chronic (1) · Hepatitis, Viral, Human (1) · Insulin Resistance (1) · Liver Diseases (1) · Multiple Myeloma (1) · Non-alcoholic Fatty Liver Disease (1)
Merck Sharp & Dohme LLC (5) · Boehringer Ingelheim (3) · Conatus Pharmaceuticals Inc. (2) · AbbVie (prior sponsor, Abbott) (1) · BioGeneric Pharma (1) · Bristol-Myers Squibb (1) · Charles University, Czech Republic (1) · Chinese University of Hong Kong (1) · Dr. Nadia AbdelAaty AbdelKader (1) · Gilead Sciences (1) · Icahn School of Medicine at Mount Sinai (1) · National Institute on Drug Abuse (NIDA) (1) · Replicor Inc. (1) · Royal Marsden NHS Foundation Trust (1) · Shanghai HEP Pharmaceutical Co., Ltd. (1)
United States (10) · Puerto Rico (4) · China (3) · Germany (3) · Australia (2) · Canada (2) · Egypt (2) · Spain (2) · United Kingdom (2) · Argentina (1) · Belgium (1) · Brazil (1) · Czechia (1) · France (1) · Iran (1)
Erin Castelloe, MD (2) · Amany Y Elkazaz (1) · Charles S Lieber, MD (1) · Chia Wang, MD, MS (1) · Daniel Cohen, MD (1) · Dina Sabry (1) · Fusheng Wang (1) · Gamal Esmat, MD (1) · Hadar J Merhav, MD (1) · Henry LY Chan, MD (1) · Mamun Al-Mahtab, MD (1)
PMID 17302380, PMID 19721480, PMID 21911884, PMID 28210927
2009 (1), 2014 (1), R21DA016066 (1)